       Document 1269
 DOCN  M9591269
 TI    A prime-boost approach to HIV preventive vaccine using a recombinant
       canarypox virus expressing glycoprotein 160 (MN) followed by a
       recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence
       Nationale de Recherche sur le SIDA.
 DT    9509
 AU    Pialoux G; Excler JL; Riviere Y; Gonzalez-Canali G; Feuillie V; Coulaud
       P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP; et al; Hopital de
       l'Institut Pasteur, Paris, France.
 SO    AIDS Res Hum Retroviruses. 1995 Mar;11(3):373-81. Unique Identifier :
       AIDSLINE MED/95306141
 AB    The safety and the immunogenicity of a recombinant canarypox live vector
       expressing the human immunodeficiency virus type 1 (HIV-1) gp160 gene
       from the MN isolate, ALVAC-HIV (vCP125), followed by booster injections
       of a soluble recombinant hybrid envelope glycoprotein MN/LAI (rgp160),
       were evaluated in vaccinia-immune, healthy adults at low risk for
       acquiring HIV-1 infection. Volunteers (n = 20) received vCP125 (10(6)
       TCID50) at 0 and 1 month, followed randomly by rgp160 formulated in alum
       or in Freund's incomplete adjuvant (FIA) at 3 and 6 months. Local and
       systemic reactions were mild or moderate and resolved within the first
       72 hr after immunization. No significant biological changes in routine
       tests were observed in any volunteer. Two injections of vCP125 did not
       elicit antibodies. Neutralizing antibodies (NA) against the HIV-1 MN
       isolate were detected in 65 and 90% of the subjects after the first and
       the second rgp 160 booster injections, respectively. Six months after
       the last boost, only 55% were still positive. Seven of 14 sera with the
       highest NA titers against MN weakly cross-neutralized the HIV-1 SF2
       isolate; none had NA against the HIV-1 LAI or against a North American
       primary isolate. Specific lymphocyte T cell proliferation to rgp 160 was
       detected in 25% of the subjects after vCP125 and in all subjects after
       the first booster injection and 12 months after the first injection. An
       envelope-specific cytotoxic lymphocyte activity was found in 39% of the
       volunteers and characterized for some of them as CD3+, CD8+, MHC class I
       restricted. The adjuvant formulation did not influence significantly the
       immune responses.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    AIDS Vaccines/ADVERSE EFFECTS/*THERAPEUTIC USE  Acquired
       Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION &  CONTROL  Adult
       Animal  Avipoxvirus/IMMUNOLOGY  CD4 Lymphocyte Count  CD4-CD8 Ratio
       CD8-Positive T-Lymphocytes/IMMUNOLOGY  Canaries  Enzyme-Linked
       Immunosorbent Assay  Female  Gene Products, env/ADVERSE
       EFFECTS/*IMMUNOLOGY  HIV Antibodies/*BLOOD  HIV
       Infections/IMMUNOLOGY/*PREVENTION & CONTROL  *HIV Seronegativity  Human
       *Immunization, Secondary  Lymphocyte Count  Male  Middle Age  Protein
       Precursors/ADVERSE EFFECTS/*IMMUNOLOGY  Time Factors  Vaccines,
       Synthetic/ADVERSE EFFECTS/*THERAPEUTIC USE  CLINICAL TRIAL  JOURNAL
       ARTICLE  MULTICENTER STUDY  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

